Efeitos da administração em curto prazo de agomelatina sobre o comportamento relacionado à depressão em ratas submetidas ao teste do nado forçado

• Autor(a) principal: Medeiros, Alana Ceres de
• Data de Publicação: 2016
• Tipo de documento: Trabalho de conclusão de curso
• Idioma: por
• Título da fonte: Repositório Institucional da UFRN
• Texto Completo: https://repositorio.ufrn.br/handle/123456789/43267
• topic: Agomelatina; Agomelatine; Depressão; Depression; Nado forçado; Forced swimming

Clinical and preclinical studies suggest agomelatine as an antidepressant drug, however few studies have been carried out in females. Depression prevalence has been assessed as being around twice higher in women than in men, and the different stages of reproduction cycle and hormonal fluctuations have been mentioned as a primary cause of certain psychiatric disorders and they might interfere on the efficacy of some antidepressants. The aim of the present study was to evaluate if agomelatine is able to alter depression-related behaviors in female rats submitted to the forced swimming test (FST). Yet it was investigated if the hormonal changes that occur during estrus stage of estrous cycle would alter the efficacy of the agomelatine. Approximately 90 days old female Wistar rats were submitted to the oral administration of saline solution – control group – or agomelatine (25, 50 and 75 mg/Kg) in a short-term treatment protocol (2-4 days previously behavioral tests). Vaginal smears were collected for determination of estrous cycle phase. The Open field test (OF) was employed in order to evaluate the locomotory activity of female rats. The results demonstrated that there was no significant alteration on the locomotion of females. Both 50 and 75 mg/Kg doses of agomelatine were able to reduce the immobility on the forced swimming test, which was not observed on the 25 mg/Kg dose. The OF and FST analysis of females rats cycling on estrus stage suggested that hormonal variations in this phase does not interfere on the efficacy of agomelatine, since dose of 75 mg/Kg reduced the immobility of females. This preclinical study contributes to the proposal of an antidepressant profile of agomelatine in females.